ERBB2 and breast carcinoma: Many studies have reported associations between high levels of TILs at diagnosis and better responses to and prognoses of neoadjuvant chemotherapy and adjuvant chemotherapy settings, particularly for triple-negative and HER2-positive breast carcinomas [12,13,14,15].